The tragedy of the national opioid epidemic has resulted in a significant increase in the number of opioid-related deaths and accordingly an increase in the number of potential donors designated Public Health Service (PHS) increased risk. Previous studies have demonstrated reluctance to use these PHS organs, and as a result, higher discard rates for these organs have been observed. All patients listed for liver transplantation in the United States from January 2005 to December 2016 were investigated. Patients on the waiting list were divided into 2 groups: those in which a PHS liver was used for transplantation (accepted PHS group) and those in which a PHS liver was declined and transplanted into a recipient lower on the match run (declined PHS group). Intention-to-treat patient survival from the time of PHS offer was significantly higher in the accepted PHS compared with the declined PHS group (P < 0.001). On Cox multivariate regression, declining a PHS donor liver was associated with a hazard ratio of 2.36 (95% confidence interval, 2.23-2.49; P < 0.001). For patients in which a PHS organ offer was declined, 11.6% died or were delisted for being too sick within the subsequent year. Donor liver allografts implanted in the accepted PHS group were of a lower donor risk index (1.28 versus 1.44) compared with the non-PHS organs that patients in the declined PHS group ultimately received if they underwent transplantation. In conclusion, there is a significantly higher survival for patients in which a PHS liver is accepted and used compared with those patients in which a PHS organ is declined. These data will help inform decisions about whether or not to accept a PHS donor liver for both patients and transplant professionals.
On the basis of guidelines from the Centers for Disease Control and Prevention and Public Health Service (PHS), donors are categorized as increased risk for disease transmission if they meet certain criteria thought to increase the risk of undetected hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).
(1) These guidelines seek to assure safety in solid organ transplantation by reducing HIV, HBV, and HCV transmission. Although the risk of transmission from a Public Health Service increased risk (PHS-IR) donor is potentially higher than a non-PHS-IR donor, the absolute risk is still very low (published risks ranging from <1 in 1000 for HCV to <1 in 10,000 for HIV). (2, 3) The transplant community continues to look for innovative ways to help address the ongoing disparity between the supply of liver grafts and the demand of much needed organs for sick patients on liver transplantation (LT) waiting lists. Despite the shortage of available liver grafts, previous studies have reported that some potential liver donors are not being maximally used. (4, 5) Indeed, Lai et al. noted that most candidates for LT who died or were removed from the waiting list received 1 or more prior offers. (6) The tragedy of the national opioid epidemic in the United States has resulted in a significant increase in the number of opioid-related deaths and accordingly an increase in the number of potential donors designated as PHS-IR. (7) The risk of death for patients on the LT waiting list is many orders of magnitude higher than the risk of transmission from a PHS-IR donor, particularly in the era of donor nucleic acid testing. (8, 9) Despite this, patients, patients' families, and transplant professionals have previously demonstrated some reluctance to use "increased risk" organs, and as a result, higher discard rates for these organs have been observed. (5, (10) (11) (12) Unlike donation after circulatory death (DCD) or HCV-positive livers in which programs must specify at the time of listing if recipients would be willing to entertain these offers, PHS-IR livers are offered to all candidates, and then the candidates/centers accept or decline the liver at the time of offer.
A previous study demonstrated noninferiority post-LT when comparing patient and graft survival in patients who underwent transplantation with PHS-IR donor livers compared with those who underwent transplantation with a non-PHS-IR liver. (13) Although these results are encouraging, there is a need to evaluate the impact of declining a PHS-IR donor liver for patients on the LT waiting list. The present study aimed to perform an intention-to-treat analysis, from the time of organ offer on the waiting list, comparing the outcomes of candidates in which a PHS-IR liver was accepted or declined.
Patients and Methods
After approval from the Mayo Clinic Institutional Review Board, data were obtained and extracted from the United Network for Organ Sharing (UNOS) standard analysis and research file. The study population included all patients listed for LT in the United States from January 1, 2005 to December 31, 2016.
Previous Organ Procurement and Transplantation Network (OPTN) guidelines were amended on July 1, 2004 to incorporate the definitions of donors at increased risk for HIV and required transplant centers to obtain specific informed consent and followup when such donor organs were used. Donors meeting these criteria were labeled "PHS high risk." In 2013, the PHS published a modified set of criteria for increased risk donors (PHS-IR) for HBV, HCV, and HIV: these definitions were incorporated into OPTN policy. (14) The present study excluded patients listed prior to 2005 in order to maintain consistency of the documentation of donors that were PHS-IR.
Patients on the waiting list were divided into 2 groups: those in which a PHS-IR liver was used for transplantation and those in which a PHS-IR liver was declined. Patients were only categorized as declining a PHS-IR liver if the decline code was 1 of the following: "patient refused," "donor social history," "donor quality or organ specific donor issue"; and if the liver was transplanted into a recipient lower on the match run. PHS-IR livers that were turned down for all other reasons or livers that ultimately were not transplanted were not included.
For the intention-to-treat analysis, patient time was calculated from the time of acceptance or decline of a PHS-IR liver meeting the above criteria. Wait-list outcomes were analyzed with previously defined methods. (15) (16) (17) Briefly, removals for death as well as for "too sick" were treated as deaths. A patient's wait-list status was therefore classified into 1 of 4 categories: death, transplanted, delisted for being too well, or still waiting/other. Records for candidates who were multilisted were combined into 1 registration.
Recipient and donor factors that were examined included recipient age, body mass index (BMI), etiology of original liver disease, calculated Model for End-Stage Liver Disease (MELD) score at listing, calculated MELD score at wait-list exit, allocation MELD score, listing for simultaneous liver-kidney transplantation (SLKT), and liver retransplantation. Donor characteristics included all components of the donor risk index (DRI) (18) as well as donor sex and BMI.
Patient survival was calculated from the time of acceptance or decline of PHS-IR liver until death or date of last follow-up. The occurrence and the date of death were obtained from data reported to the Scientific Registry of Transplant Recipients (SRTR) and were completed by data from the US Social Security Administration and from OPTN.
All statistical analyses were performed using STATA 12 (Stata Corp., College Station, TX). Differences between groups were analyzed using the unpaired t test for continuous variables and by the v 2 test or continuity correction method for categorical variables. Wilcoxon rank sum was used for variables that did not display a normal distribution. Survival curves for patient or graft survival were generated using the Kaplan-Meier method and compared by the logrank test. Cox proportional hazard multivariate regression with backward stepwise selection for patient survival was performed using wait-list characteristics. A liberal retention criteria of P < 0.15 was used. Separate models were also fitted for several MELD subgroups. (19) All statistical tests were 2-sided, and differences were considered significant when P < 0.05.
Results
In the study period between January 1, 2005, and December 31, 2016, a total of 9851 LTs using PHS-IR donors were performed (accepted PHS-IR Group). During the same study period, a total of 56,106 candidates had a PHS-IR liver that was declined for 1 of the aforementioned refusal codes and that was subsequently transplanted in another candidate lower on the match run (declined PHS-IR group).
The annual number of LTs using PHS-IR organs increased significantly on linear regression over the 12-year study period (P < 0.001; Fig. 1 ). The large increase between 2013 and 2014 corresponded to the modification of the definition of PHS-IR.
Recipient characteristics for the 2 groups can be seen in Table 1 . Mean recipient age at listing was 53.1 6 13.7 years in the accepted PHS-IR and 51.6 6 16.4 years in the declined PHS-IR groups (P < 0.001). A higher proportion of patients had HCV as the etiology of their liver disease in the accepted PHS-IR group (45.5%) compared with the declined PHS-IR group (41.1%; P < 0.001). The number of patients with a diagnosis of alcohol, nonalcoholic steatohepatitis (NASH), and cholestatic liver disease was also higher in the accepted PHS-IR group, whereas the proportion of patients with diagnosis "other" was higher in the declined PHS-IR group. The number of patients with a diagnosis of hepatocellular carcinoma (HCC) was 2240 (22.7%) in the accepted PHS-IR and 8010 (14.3%) in the declined PHS-IR groups (P < 0.001). Both MELD score at listing (19.3 6 10.1 versus 15.5 6 8.0; P < 0.001) and calculated MELD score at the time of the PHS-IR offer (22.6 6 11.0 versus 19.5 6 11.2; P < 0.001) were higher in the accepted PHS-IR group compared with the declined PHS-IR group. Allocation MELD score was higher in the accepted PHS-IR compared with the recipients in the declined PHS-IR group who were ultimately transplanted with another liver (27.5 6 7.6 versus 22.9 6 10.0; P < 0.001).
Donor characteristics in the accepted PHS-IR and declined PHS-IR groups who were ultimately transplanted with another liver can be seen in Table 2 . Recipients in the accepted PHS-IR group received a donor liver with a significantly lower DRI (1.28 6 0.30) than the donor liver ultimately received by recipients in the declined PHS-IR group who underwent transplantation (1.44 6 0.35; P < 0.001). Donor livers in the accepted PHS-IR group were younger in age (34.3 6 13.4 versus 40.0 6 18.1 years; P < 0.001), had a lower cold ischemia time (CIT; 6.5 6 2.9 versus 6.6 6 3.1 hours; P 5 0.006), were more likely to be Caucasian (69.6% versus 64.3%; P < 0.001), were more likely to have a cause of death of anoxia (45.0% versus 24.2%; P < 0.001), and were more likely to be regional (28.0% versus 22.9%; P < 0.001) or national share (6.3% versus 4.6%; P < 0.001). The median number of PHS-IR donor liver turndowns in the decline PHS-IR group was 2 (range, 1-20; Fig. 2 ). The median waiting time following declining a PHS-IR liver donor until getting transplanted with another liver was 105 days (range, 1-3274 days). Significant variation was seen in acceptance rates per listed patient by region (P < 0.001). Region 10 (28.1%) and region 3 (19.1%) had the highest acceptance rates, whereas region 5 (10.9%) and region 9 (11.2%) had the lowest. Variation was also seen in transplant center acceptance rates (4.0%-51.5%; P < 0.001).
Intention-to-treat patient survival from the time of PHS-IR offer was significantly higher in the accepted PHS-IR compared with the declined PHS-IR group (P < 0.001). Patient survival from the time of offer at 1, 3, and 5 years was 90.2%, 82.2%, and 75.5% in the accepted PHS-IR group and 80.5%, 67.6%, and NOTE: Data are given as n (%) and mean 6 standard deviation. *In the n 5 9851 accepted PHS and n 5 22,882 declined PHS patients who were ultimately transplanted. NOTE: Data are given as n (%) and mean 6 standard deviation.
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59.4% in the declined PHS-IR group (Fig. 3) . For patients in the declined PHS-IR group at 1 year following the declined PHS-IR offer, 31.2% of patients underwent transplantation with a different organ and 11.6% of patients died or were delisted for being too sick. At completion of the study period for patients in the declined PHS-IR group, 57.8% of patients underwent transplantation, and 29.3% of patients died or were delisted for being too sick.
Recipient wait-list characteristics were investigated in a Cox model investigating intention-to-treat patient survival from the time of PHS-IR offer. A Cox multivariate regression model with backward stepwise selection and liberal retention criteria of P < 0.15 was performed (Table 3) . Variables retained in the model included the following: declining a PHS-IR donor liver (hazard ratio [HR], 2.36; P < 0.001), listing MELD score (HR, 1.03; P < 0.001), HCC exception status (HR, 0.73; P < 0.001), SLKT listing (HR, 1.22; P < 0.001), liver retransplant status (HR, 1.28; P < 0.001), and era after 2013 changes to the PHS definition (HR, 1.13; P < 0.001). None of the other variables were significant in the multivariate model. Separate models were also fitted for several MELD subgroups. The HR by MELD score for patients in the declined PHS-IR versus the accepted PHS-IR groups can be seen in Fig. 4 
Discussion
The US national death rates from drug overdose have nearly doubled since 2003, with over 47,000 deaths in 2014. (20) One consequence of this devastating national epidemic has been to yield an increase in the number of potential organ donors meeting the definition of PHS-IR. The greatest relative increase in the mechanisms of death among deceased donors from 2003 to 2014 was drug overdose. (20) The reluctance to use PHS-IR, as demonstrated by higher discard rates for these organs, has been described previously. (5) Because of the ongoing disparity between the supply of liver grafts and the demand of sick patients on LT waiting lists, it is important to assess the outcomes of declining or accepting a PHS-IR donor liver for patients on the waiting list. The present study demonstrates a significantly higher survival for patients in which a PHS-IR liver was accepted and used compared with those patients in which a PHS-IR liver was declined. Although the advantage of accepting a PHS-IR liver was highest for those patients with a MELD score 35, we demonstrate that a survival advantage still existed even for patients with lower MELD scores. These survival advantages remained even after adjustment for a variety of recipient variables including MELD score and disease etiology.
In a previous study investigating national SRTR data, patients undergoing LT with a PHS-IR liver graft were compared with patients undergoing transplantation with non-PHS-IR liver grafts. In unadjusted posttransplant analysis, patients undergoing transplantation with a PHS-IR liver had superior graft and patient survival. (13) In the present study, we observed that the donor liver grafts received by the accepted PHS-IR group were younger (34.3 years) and were of a lower DRI (1.28) compared with the non-PHS-IR organs that patients in the declined PHS-IR group ultimately received if they underwent transplantation. These findings are consistent with previous publications and suggest that recipients are exchanging the extremely low risk of infectious transmission for an older and higher DRI liver. (21) In our analysis, the median number of PHS-IR donor turndowns for patients in the declined PHS-IR group was 2, with a median waiting time following declining a PHS-IR liver donor until getting transplanted with another liver being 105 days. These data support previous more general literature on organ turndowns, which demonstrated that most candidates for LT who died or were removed from the waiting list received 1 or more offers prior. (6) More importantly, in the present study, 11.6% of patients who declined a PHS-IR organ offer died or were delisted for being too sick within the subsequent year.
Historically, the reluctance of using increased amounts of PHS-IR donors has likely been both emotional and fear driven. A previous survey of 422 transplant surgeons suggested that only 52.7% had ever used organs from PHS-IR donors. (10) Another survey of patients on the kidney waiting list found that most patients on the kidney waiting list felt that accepting a PHS-IR kidney was only appropriate when death was imminent and should be considered a last resort. (22) However, with both a better understanding of the associated risks and with the advent of curative treatment for HCV and highly effective and generally welltolerated therapies for HIV, the reluctance to use PHS-IR donors has softened. (23, 24) The very small risk of infection from PHS-IR donors must be balanced against the known benefits of transplantation. Counseling of potential recipients of PHS-IR organs should focus on both education of the low likelihood of bloodborne virus transmission and that effective treatments are available in the unlikely event that they are exposed. Transplant centers using PHS-IR donors also need to have systematic monitoring programs for all recipients of these organs so that any transplant-transmitted viral infections can be identified for early treatment and mandatorily reported to UNOS. (14) Interestingly, the transplant center the patient was listed at was highly correlated with acceptance of a PHS-increased liver, whereas acceptance rates by recipient education level and race were similar. This may suggest that education by the transplant center and transplant center acceptance practices play a larger role than recipient demographics.
Because informed consent is a key component of the utilization of PHS-IR donors, it is important for transplant centers to develop a comprehensive program to optimize the usage of these organs. Previous authors have described such programs that include patient information materials as well as counseling from educated health care professionals. (25) Educating both referring providers as well as local organ procurement organizations to the changing landscape of PHS-IR donors is also paramount. As more data similar to that presented herein become available, future discussion may also include insurance providers to ensure that antiviral medications, such as those used to treat HCV, are covered in the rare instance of viral transmission. The financial benefits of earlier transplantation for patients on the waiting list, with its lower resource utilization and total cost of care, would likely more than offset the costs of antivirals for the small subset of any patients exposed to blood-borne virus transmission. Although the data in the present study look only at LT, it seems reasonable that the benefits of using PHS-IR organs can likely be extrapolated to other organ groups. In a recent study by Bowring et al., wait-list candidates who accepted a PHS-IR kidney were at 33% lower risk of death at 1-6 months and a 48% lower risk of death beyond 6 months after the decision compared with candidates who declined a PHD-IR kidney. (26) These findings in addition to those in the present study, underscore the need for further studies investigating the implications of declining these organs for other organ groups.
Limitations of the present study include its reliance on UNOS registry data, which lack a high degree of granular detail. Although patient decline codes were investigated and only those felt to be appropriate were included, it was not possible to determine if the choice to decline was made by the patient, the transplant center, or both. The present study also does not have any specific data on HBV, HCV, or HIV seroconversion rates for any of the recipients of PHS-IR livers.
In conclusion, this study demonstrates a significantly higher survival for patients in which a PHS liver was accepted and used compared with those patients in which a PHS liver was declined. These survival advantages remained even after adjustment for a variety of recipient variables including MELD score and disease etiology. In addition, patients in the accepted PHS group received donor liver allografts that were younger and were of a lower DRI compared with the non-PHS organs that patients in the declined PHS group ultimately received if they underwent transplantation. In light of these data, it is important to educate both patients and transplant providers on the risks and benefits of accepting a PHS-IR donor.
